tezepelumab

Home
Ligands
tezepelumab

GtoPdb Ligand ID: 8933

tezepelumab is an approved drug (FDA (2021), ENA (2022))

Comment: Tezepelumab is a fully human IgG2λ monoclonal antibody, that is a potential first-in-class agent that blocks the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP- which is an upstream modulator of multiple inflammatory pathways). It is being investigated for its immunomodulatory action.

References
1. Agnihotri G, Lio PA. (2020) Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials. Clin Drug Investig, 40 (5): 421-431. [PMID:32172523]
2. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. (2017) Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med, 377 (10): 936-946. [PMID:28877011]
3. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C et al.. (2014) Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med, 370 (22): 2102-10. [PMID:24846652]
4. Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å, Mo M et al.. (2020) NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res, 21 (1): 266. [PMID:33050934]
5. Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G. (2020) DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res, 21 (1): 279. DOI: 10.1186/s12931-020-01541-7 [PMID:33087119]
6. Soumelis V, Liu YJ. (2004) Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin Immunopathol, 25 (3-4): 325-33. [PMID:14999427]
7. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A et al.. (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol, 3 (7): 673-80. [PMID:12055625]
8. Wechsler ME, Colice G, Griffiths JM, Almqvist G, Skärby T, Piechowiak T, Kaur P, Bowen K, Hellqvist Å, Mo M et al.. (2020) SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res, 21 (1): 264. DOI: 10.1186/s12931-020-01503-z [PMID:33050928]
9. Ying S, O'Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, Robinson D, Zhang G, Zhao J, Lee TH et al.. (2005) Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol, 174 (12): 8183-90. [PMID:15944327]

References

1. Agnihotri G, Lio PA. (2020)
Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials.
Clin Drug Investig, 40 (5): 421-431. [PMID:32172523]

2. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. (2017)
Tezepelumab in Adults with Uncontrolled Asthma.
N Engl J Med, 377 (10): 936-946. [PMID:28877011]

3. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C et al.. (2014)
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
N Engl J Med, 370 (22): 2102-10. [PMID:24846652]

4. Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å, Mo M et al.. (2020)
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res, 21 (1): 266. [PMID:33050934]

5. Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G. (2020)
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res, 21 (1): 279. DOI: 10.1186/s12931-020-01541-7 [PMID:33087119]

6. Soumelis V, Liu YJ. (2004)
Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation.
Springer Semin Immunopathol, 25 (3-4): 325-33. [PMID:14999427]

7. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A et al.. (2002)
Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.
Nat Immunol, 3 (7): 673-80. [PMID:12055625]

8. Wechsler ME, Colice G, Griffiths JM, Almqvist G, Skärby T, Piechowiak T, Kaur P, Bowen K, Hellqvist Å, Mo M et al.. (2020)
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Respir Res, 21 (1): 264. DOI: 10.1186/s12931-020-01503-z [PMID:33050928]

9. Ying S, O'Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, Robinson D, Zhang G, Zhao J, Lee TH et al.. (2005)
Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity.
J Immunol, 174 (12): 8183-90. [PMID:15944327]